Drug intelligence / Profile preview

NPD-0614

Development stage: Preclinical
Lead developer: Nogra Pharma
Modality: Small Molecules
Administration: Intraperitoneal

Overview

NPD-0614 is a preclinical-stage small molecule drug candidate developed by Nogra Pharma. It functions as a selective androgen/hormone receptor modulator (SAhRM) targeting the androgen receptor. The compound is being investigated for the treatment of immune-inflammatory-mediated diseases. As a SAhRM, NPD-0614 is designed to provide tissue-selective modulation of androgen receptor signaling, aiming to harness the anti-inflammatory properties of androgen signaling while avoiding the systemic side effects typically associated with conventional androgen therapies.

Targets

AHR (Aryl hydrocarbon receptor)

Beyond the preview

Go deeper on NPD-0614.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NPD-0614.

Explore the full profile